Corcept Therapeutics Stock
Corcept Therapeutics Incorporated
Company data
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Country
- United States
- CEO
- Joseph K. Belanoff
- Employees
- 730
- Market cap
- $11.9 B
- IPO
- 14/04/2004
Corcept Therapeutics Incorporated is a healthcare company operating in the medical, pharmaceuticals industry, headquartered in Redwood City, USA. Founded in 1998, the firm is dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Corcept Therapeutics stock: price history
1D
-2.8%
1W
-9.1%
1M
-1.5%
6M
+138.6%
YTD
+216.6%
1Y
+38.6%
2Y
+133.0%
5Y
+449.7%
10Y
+1,659.7%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~5% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Corcept Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
1 more assignment (Enabler/Second row) Pro-only.
Corcept Therapeutics is a pharmaceutical company specializing in the research, development, and commercialization of drugs for severe metabolic, oncology, and neuropsychiatry diseases. Its primary commercial product is Korlym, used to treat endogenous Cushing's syndrome in patients with hyperglycemia. Additionally, the company maintains an extensive research pipeline based partly on the development of cortisol modulators for indications such as advanced ovarian tumors and antipsychotic-induced weight gain.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Corcept Therapeutics
Analyst assessment of Corcept Therapeutics
PRICE TARGET LOW
US$50.00
CONSENSUS
US$125.33
MEDIAN
US$142.50
PRICE TARGET HIGH
US$165.00
0
STRONG BUY
14
BUY
9
HOLD
3
SELL
0
STRONG SELL
26
TOTAL · Buy
As of: 18/09/2026
Corcept Therapeutics stock metrics
P/E
211.85
P/B
16.45
EV/EBITDA
410.1
RETURN ON EQUITY
6.0%
NET MARGIN
16.5%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
88.6%
FLOAT SHARES
95,774,612
AVG. DAILY VOLUME (30D)
1,403,310
Insider transactions (SEC)
WILSON JAMES N
WILSON JAMES N
WILSON JAMES N
Vieira Roberto Wandenkolk
Vieira Roberto Wandenkolk
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.8%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Corcept Therapeutics stock
What does Corcept Therapeutics do?
Corcept Therapeutics Incorporated is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in United States.
The CEO is Joseph K. Belanoff, the company employs around 730 people.
The IPO was on 14/04/2004; the stock trades on NASDAQ under the ticker CORT.
What do analysts say about Corcept Therapeutics stock?
26 analysts rate the stock, the consensus is Buy (as of 18/09/2026).
The average price target is US$125.33, ranging from US$50.00 to US$165.00, with a median of US$142.50.
This is an external assessment, not a statement by Market Jury.
When does Corcept Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -5% stronger than usual.
Does Corcept Therapeutics pay a dividend?
No, Corcept Therapeutics currently does not pay a dividend.
Which stocks are comparable to Corcept Therapeutics?
Comparable stocks include Liquidia, Latigo Biotherapeutics, Helus Pharma, Eli Lilly and Company, Johnson & Johnson, AbbVie, Merck & and UnitedHealth Group.
How can I get Corcept Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Corcept Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.